Back to search

Peptide record

TPDB40565

P09 Anticancer standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB40565
P09
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 13-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Sequence
AAGTLYTYPENWR
Physicochemical Analysis
C71H100N18O21
DCQHIKMFSV
ATY
1541.68
6.84
1
1
6
-0
-0.64
-0.846
45.38
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
8480
550.05
5
Residue Composition
number
2
A
1
R
1
N
0
D
0
C
1
E
0
Q
1
G
0
H
0
I
1
L
0
K
0
M
0
F
1
P
0
S
2
T
1
W
2
Y
0
V
Amino Acid Distribution
A: 2 R: 1 N: 1 D: 0 C: 0 E: 1 Q: 0 G: 1 H: 0 I: 0 L: 1 K: 0 M: 0 F: 0 P: 1 S: 0 T: 2 W: 1 Y: 2 V: 0
Chemical Descriptors
13
C71H100N18O21
1541.68
6.84
-0
-0.64
-0.846
Free
L
Linear
Free
Anticancer
Eukaryotic Translation Elongation Factor 1 Gamma (Eef1G) fragment
Evidence Records 2 records
Evidence 1 Activity

Activity

Relative viability
Relative viability = 0.85 at 50 µg/ml
Anticancer

Target

Bone Cancer
MG-63
Bone

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

Relative viability
Relative viability = 1.07 at 50 µg/ml
Anticancer

Target

Bone Cancer
U-2 OS
Bone

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023